VENLO, Netherlands - QIAGEN (NYSE:QGEN), a healthcare diagnostics company with a market capitalization of nearly $10 billion and impressive 80% gross profit margins, has secured CE-IVDR certification ...
NEW YORK – Epigenetics firm VolitionRx and Werfen said Tuesday that they have signed a licensing and commercialization deal covering the use of Volition's antiphospholipid syndrome (APS) test with ...
NEW YORK – Spanish diagnostic firm MiMark Diagnostics is progressing toward clinical validation and commercialization of its minimally invasive test for endometrial cancer. The spinout of Vall ...
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback